Currently recommended antiretrovirals consist of a variety of agents from different drug classes. Differences in mechanism of action result in unique combinations that allow for additive interactions and synergy, leading to increased therapeutic success. However, overlapping toxicities place patients at risk of increased adverse effects such as hepatotoxicity and endocrine abnormalities. A summary of the pharmacological and pharmacokinetic considerations is given in Table 3.1 for currently available nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, protease inhibitors, entry inhibitors, fusion inhibitors, integrase inhibitors, and pharmacokinetic enhancers.
Abel S, Back DJ, Vourvahis M (2009) Maraviroc: pharmacokinetics and drug interactions. Antivir Ther 14(5):607–618PubMedGoogle Scholar
Cottrell ML, Hadzic T, Kashuba AD (2013) Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet 52(11):981–994CrossRefPubMedPubMedCentralGoogle Scholar
Ramanathan S, Mathias AA, German P, Kearney BP (2011) Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet 50(4):229–244CrossRefPubMedGoogle Scholar